强生公司产品展示 - 强生公司在BofA Securities Health Care Conference上展示了其在肿瘤学、免疫学和神经科学领域的强劲动力[4] - DARZALEX成为强生公司目前最畅销的产品，取代了之前的STELARA，而且在前线治疗中取得了越来越多的进展[11][12] - CARVYKTI在晚期治疗中表现出色，且随着生产能力的提升，强生公司计划将其推广至更早期的治疗阶段[19][20][21] - 强生公司在不同治疗阶段推出的CAR-T细胞疗法和双特异性抗体有望为患者提供更多选择，以满足不同患者的需求和偏好[36][37] - 强生公司不断创新，正在研发更多新型分子，如能同时作用于多个靶点的三特异性抗体，以应对患者可能出现的耐药问题[40] 强生公司液体肿瘤领域发展 - 在液体肿瘤领域，强生公司采取多种策略，包括开发BTK抑制剂IMBRUVICA和不同类型的CAR-T细胞疗法，以提供更全面的治疗选择[42][44] - 公司正在致力于开发多功能生物制剂和多功能CAR-T细胞，尝试突破创新领域的下一波浪潮[45][46] - 公司在前列腺癌领域开发CAR-T细胞，针对KOK2，这是目前最具选择性的前列腺癌标记物之一[45] - 公司的CAR-T细胞针对PSMA和CD28双特异性抗体等靶点，采用多种方法进行治疗，以应对癌症[46] 强生公司膀胱癌治疗成果 - 公司开发了一种药物-器械组合，用于早期膀胱癌治疗，取得了前所未有的完全缓解率[51][52] - 公司的药物-器械组合在膀胱癌治疗中表现出色，取得了83%的完全缓解率和85%的持续缓解率[52] - 公司的药物-器械组合采用不同技术，释放药物的速率稳定，取得90%以上的完全缓解率[53] - 公司的药物-器械组合在膀胱癌治疗中具有优异的耐受性和疗效，受到医生和患者的青睐[54][55] - 公司的药物-器械组合操作简便，可由护士进行，为患者提供更便利的治疗选择[56] 强生公司肺癌治疗方案 - 公司在肺癌领域开发lazertinib/RYBREVANT组合治疗方案，取得出色的临床数据，正在等待批准[60][61] - 公司的lazertinib/RYBREVANT组合治疗方案在肺癌治疗中表现出色，取得优异的无进展生存期数据[66] - 公司正在优化lazertinib/RYBREVANT组合治疗方案，提高患者耐受性和便利性，以进一步优化治疗效果[69] - 公司的lazertinib/RYBREVANT组合治疗方案为患者提供了无需化疗的选择，受到医生和患者的欢迎[77] 强生公司新药研发 - 公司正在进行2113项目的研发，该项目是一种靶向口服肽，对IL-23受体进行抑制，取得了良好的临床数据[85] - 公司的2113项目在牛皮癣治疗中表现出色，患者积极参与临床试验，显示出口服治疗的潜在优势[86] - 公司的2113项目采用复杂的环肽结构，口服给药，稳定性强，疗效显著，受到患者和医生的青睐[90] 强生公司合作与收购 - 公司在合作方面拥有广泛的合作议程，通过创新中心和J-Labs等方式寻找有趣的技术和资产，推动公司的发展[96] - 公司在平台和产品方面都有所作为，如与主角合作导致IL-23抑制剂2113的开发[97] - 公司收购了Serotonin公司，该公司拥有一种AI技术，可以高效优化CAR-T构建[97] - 公司与Cellular Origins合作，在机器人和自动化方面进行制造[97]

Whether it's through stocks, bonds, ETFs, or other types of securities, all investors love seeing their portfolios score big returns. But for income investors, generating consistent cash flow from each of your liquid investments is your primary focus. While cash flow can come from bond interest or interest from other types of investments, income investors hone in on dividends. A dividend is that coveted distribution of a company's earnings paid out to shareholders, and investors often view it by its dividen ...

Kenvue (NYSE:KVUE) stock is in the news Monday after the company announced that Johnson & Johnson (NYSE:JNJ) is selling its stake in the business. Kenvue has announced a secondary offering that will have Johnson & Johnson selling its entire stake of 182,329,550 shares of KVUE stock. It is exchanging these shares for the indebtedness of JNJ held by Goldman Sachs & Co. LLC and J.P. Morgan. After this debt-for-equity exchange, the selling shareholders will sell the shares of KVUE stock to the underwriters of t ...

强生公司股息表现 - 强生公司拥有超过六十年的连续增长股息的优秀纪录[1] - 强生公司最近宣布将每股季度股息提高至1.24美元，年化为4.96美元，比之前的支付额增加了4.2%[3] - 强生公司的股息率为3.3%，是标普500指数的两倍以上，每投资1000美元可产生大约33美元的年度股息收入[4] 强生公司财务状况 - 强生公司在2023年产生约180亿美元的自由现金流，轻松覆盖了118亿美元的股息支付，资产负债表强健，拥有260亿美元的现金和仅7亿美元的净债务[5] 强生公司股息增长记录 - 强生公司已连续62年提高股息，被称为“股息之王”，并且具有稳定的股息增长记录[5] - 强生公司是一家非常健康的股息股票，具有出色的股息增长记录[6] 强生公司股息收益率 - 强生公司提供更高的股息收益率，并以健康的财务状况支持其支付，使其成为一个稳固的长期持有的股息股票[7]

Most investors are well aware that the S&P 500 was down 1.6% at the end of April. However, the ongoing earnings season and the promise of at least one rate cut later in the year have helped stocks keep momentum. Experienced investors are aware of the fact that market ups and downs are common. Simply put, it is just not possible to time the market. Instead, consider this as a time to buy the most undervalued S&P 500 stocks that have the potential to move higher as the economy improves. These well-known indus ...

The stock market has performed well so far this year, with benchmark indices rising over 9%. After recovering from a dip in April, indices are nearing record highs set in March and could soon score new records. While past performance is positive, high valuations have reignited discussions around a potential market correction. The S&P 500‘s price-to-earnings (P/E) ratio is close to 27, above its 10-year median of 15. This suggests the market may be indeed overvalued and due for a pullback. Some investors cho ...

Johnson & Johnson (NYSE:JNJ) stock is a hot topic on Wednesday after the company proposed a $6.5 billion settlement over talc cancer lawsuits. Johnson & Johnson is seeking to bankrupt LTL Management as part of its settlement proposal. This is a subsidiary that was created for the sole purpose of absorbing the company’s talc cancer lawsuits. Previous attempts at this have been made but the court blocked it both times. This time around claimants will get to vote on the matter. Johnson & Johnson claims that th ...

Johnson & Johnson on Wednesday proposed a plan to pay nearly $6.5 billion to resolve tens of thousands of lawsuits claiming that its cosmetic talc-based powder causes cancer. Through a bankruptcy filing of its subsidiary company, LTL Management, J&J will be able to resolve about 99.75% of the pending talc lawsuits against the company and its affiliates in the U.S. Courts have rebuffed J&J's two previous efforts to resolve the lawsuits through the bankruptcy of the subsidiary created to absorb the company's ...

Key Takeaways Johnson & Johnson on Wednesday proposed a settlement that would pay roughly $6.5 billion to settle lawsuits alleging the company's talc powder caused cancer. The settlement would resolve nearly all of the pending suits against J&J and its subsidiaries, the company said. Claimants would have three months to vote for or against the settlement package. Johnson & Johnson (JNJ) shares rose in early trading Wednesday after the company announced a plan that would resolve nearly all pending litigation ...

Johnson & Johnson (JNJ.N) announced on Wednesday a significant move towards resolving ongoing litigation over its baby powder and other talc products, with a proposed settlement amounting to $6.475 billion. Are you looking for signals & alerts from pro-traders? Sign-up to Invezz Signals™ for FREE. Takes 2 mins. This substantial figure is aimed at settling tens of thousands of lawsuits alleging that the company’s talc products contain asbestos and could cause ovarian cancer. Johnson & Johnson plans settlemen ...